Skip to main content
. 2021 Jun 22;81(17):4581–4593. doi: 10.1158/0008-5472.CAN-20-3323

Figure 3.

Figure 3.

Nelfinavir impairs intracellular trafficking, plasma membrane deposition, and secretion of ER-resident proteins. A, FRAP of CFP-Rab1A protein in the Golgi of control, untreated cells, or cells pretreated for 3 hours with increasing doses of nelfinavir. B, Representative picture of TNFα–eGFP retained in the ER of the U-2 OS cells after 3 hours treatment with 10 μmol/L brefeldin A or 20 μmol/L nelfinavir. For the movies showing trafficking of TNFα–eGFP after the treatment, see Supplementary Movie S1A–S1C. For the quantification of TNFα–EGFP signal retained in the cell after exposure to nelfinavir and other drugs, see Supplementary Fig. S6. C, IgA secretion in AMO-1 multiple myeloma after treatment for 3 hours with 10 μmol/L brefeldin A or 10 and 20 μmol/L nelfinavir. D, Surface expression of MHC class I on AMO-1 cells after treatment for 3 hours with brefeldin A or 10 and 20 μmol/L nelfinavir. Data for C and D represent means ±SD from three independent replicates, statistically significant differences are marked. ***, P < 0.001.